[Cytoprotective and Antiangiogenic Effects of the Multikinase Inhibitor Sorafenib on Human Retinal Pigmentepithelium]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2011 Jan 22

PMID 21253747

Citations 3

Authors

M Kernt

S Thiele

C Hirneiss

A S Neubauer

C A Lackerbauer

A Wolf

K H Eibl

C Haritoglou

M W Ulbig

A Kampik

Affiliations

Soon will be listed here.

Abstract

Background: Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor A (VEGF) is the main target of current antiangiogenic treatment strategies for AMD. Previous reports indicated that sorafenib, an oral multikinase inhibitor, might have beneficial effects on exudative AMD. This study investigates the effects of sorafenib on light-induced overexpression of VEGF and its receptors VEGFR1 and 2 in human retinal pigment epithelial (RPE) cells.

Methods: The effects of sorafenib on VEGFR1 and 2 expression of primary human RPE cells was investigated by reverse transcription polymerase chain reaction (RT-PCR), immunohistochemistry and western blotting. In addition, RPE cells were exposed to white light and incubated with sorafenib. Viability, expression of VEGF and its mRNA were determined by RT-PCR, immunohistochemistry, western blotting, and enzyme-linked immunosorbent assays.

Results: Sorafenib reduced VEGFR1 and 2 expression of RPE cells. Light exposure decreased cell viability and increased expression and secretion of VEGF. These light-induced effects were significantly reduced when cells were treated with sorafenib at a dose of 1 µg/ml.

Conclusion: The results show that sorafenib has promising properties as a potential antiangiogenic treatment for AMD.

Citing Articles

Subconjunctival Delivery of Sorafenib-Tosylate-Loaded Cubosomes for Facilitated Diabetic Retinopathy Treatment: Formulation Development, Evaluation, Pharmacokinetic and Pharmacodynamic (PKPD) Studies.

Madhusudhan S, Gupta N, Rahamathulla M, Chidambaram S, Osmani R, Ghazwani M Pharmaceutics. 2023; 15(10).

PMID: 37896180 PMC: 10610393. DOI: 10.3390/pharmaceutics15102419.

Medication Trends for Age-Related Macular Degeneration.

Cho Y, Park D, Jeon I Int J Mol Sci. 2021; 22(21).

PMID: 34769270 PMC: 8584051. DOI: 10.3390/ijms222111837.

Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib.

Tian L, Ren B, Gao X, Luo Y, Cai Y, Zhou K Int J Ophthalmol. 2014; 7(2):198-204.

PMID: 24790858 PMC: 4003070. DOI: 10.3980/j.issn.2222-3959.2014.02.03.

References

Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E . Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2000; 108(2):106-9. DOI: 10.1055/s-2000-5803. View

Miyamoto N, De Kozak Y, Jeanny J, Glotin A, Mascarelli F, Massin P . Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2006; 50(2):461-70. DOI: 10.1007/s00125-006-0539-2. View

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D . Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66(24):11851-8. DOI: 10.1158/0008-5472.CAN-06-1377. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Kernt M, Liegl R, Rueping J, Neubauer A, Haritoglou C, Lackerbauer C . Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor. Growth Factors. 2010; 28(3):211-20. DOI: 10.3109/08977191003604505. View

Neubauer A, Holz F, Sauer S, Wasmuth T, Hirneiss C, Kampik A . Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system. Clin Ther. 2010; 32(7):1343-56. DOI: 10.1016/j.clinthera.2010.07.010. View

Klein R, Klein B, Linton K . Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992; 99(6):933-43. DOI: 10.1016/s0161-6420(92)31871-8. View

Adnane L, Trail P, Taylor I, Wilhelm S . Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006; 407:597-612. DOI: 10.1016/S0076-6879(05)07047-3. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

10.

Nilsson S, Sundelin S, Wihlmark U, Brunk U . Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc Ophthalmol. 2003; 106(1):13-6. DOI: 10.1023/a:1022419606629. View

11.

van Wijngaarden P, Coster D, Williams K . Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005; 293(12):1509-13. DOI: 10.1001/jama.293.12.1509. View

12.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

13.

Marmor M . Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol. 2000; 97(3-4):239-49. DOI: 10.1023/a:1002192829817. View

14.

Cruickshanks K, Klein R, Klein B, Nondahl D . Sunlight and the 5-year incidence of early age-related maculopathy: the beaver dam eye study. Arch Ophthalmol. 2001; 119(2):246-50. View

15.

Rosenfeld P, Fung A, Puliafito C . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005; 36(4):336-9. View

16.

Holz F, Pauleikhoff D, Klein R, Bird A . Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol. 2004; 137(3):504-10. DOI: 10.1016/j.ajo.2003.11.026. View

17.

Kernt M, Staehler M, Stief C, Kampik A, Neubauer A . Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol. 2007; 86(4):456-8. DOI: 10.1111/j.1600-0420.2007.01014.x. View

18.

Diago T, Pulido J, Molina J, Collett L, Link T, Ryan Jr E . Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc. 2008; 83(2):231-4. PMC: 2763274. View

19.

Takahashi H, Tamaki Y, Ishii N, Oikawa N, Mizuguchi E, Francis J . Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res. 2008; 33(11):1002-10. DOI: 10.1080/02713680802492440. View

20.

Cruickshanks K, Klein R, Klein B . Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol. 1993; 111(4):514-8. DOI: 10.1001/archopht.1993.01090040106042. View